Xenon Pharmaceuticals Inc XENE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Xenon Halts Trial Enrollment After Adverse Events
Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner
Trading Information
- Previous Close Price
- $39.17
- Day Range
- $38.59–40.52
- 52-Week Range
- $33.38–72.66
- Bid/Ask
- $39.25 / $39.91
- Shares Outstanding
- 96.84M
- Market Cap
- $3.92B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 370
- Website
- https://www.xenon-pharma.com
Valuation
Metric | XENE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | XENE |
|---|---|
Quick Ratio | 20.71 |
Current Ratio | 21.02 |
Interest Coverage | — |
Quick Ratio
XENE
Profitability
Metric | XENE |
|---|---|
Return on Assets (Normalized) | −37.97% |
Return on Equity (Normalized) | −40.08% |
Return on Invested Capital (Normalized) | −43.19% |
Return on Assets
XENE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&!y@ZL | LOCK|>#^! | $140B | |||
| Moderna Inc MRNA | LOCK|<R>%>?M | LOCK|ZR | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<K^kFT | LOCK|fWc^n | $95B | |||
| argenx SE ADR ARGX | LOCK|l@<@mTp | LOCK|mQ | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|CGFV!^ | LOCK|<^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|V@pMHZQk | LOCK|%<&! | $31B | |||
| Incyte Corp INCY | LOCK|mB!>#V | LOCK|!? | $25B | |||
| BioNTech SE ADR BNTX | LOCK|d>$B$X | LOCK|&> | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$B<PJ^H | LOCK|<^yvD | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!@q&J#$ | LOCK|qz | $16B |
United States